Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
AERIE PHARMACEUTICALS INC (AERI) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/21/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Amended and Restated Certificate of Incorporation of Aerie Pharmaceuticals, Inc",
"each outstanding Share of restricted stock of the Company (a “Company Restricted Stock”) that vested solely on the passage of time, whether or not vested, was cancelled and the holder thereof became entitled to receive a cash payment equal to the Merger Consideration with respect to each Share of time-vested Company Restricted Stock, whether or not vested, held by such holder (without regard to vesting);",
"First Supplemental Indenture, by and between Aerie Pharmaceuticals, Inc. and Wilmington Trust, National Association"
11/18/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/07/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/03/2022 8-K Quarterly results
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Overview Presentation dated September 2022"
08/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement and Plan of Merger, by and among the Company, Parent and Merger Sub",
"Agreement and Plan of Merger, by and among the Company, Parent and Merger Sub"
08/04/2022 8-K Quarterly results
Docs: "Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update"
08/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease"
06/13/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/11/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Overview Presentation dated April 2022",
"Company Overview Presentation dated April 2022"
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer"
03/04/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
01/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Overview Presentation dated January 2022",
"Company Overview Presentation dated January 2022"
12/16/2021 8-K Quarterly results
12/07/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update"
10/21/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Building a Global Netarsudil Franchise",
"Building a Global Netarsudil Franchise"
10/20/2021 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
10/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan"
10/07/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRINT® Drug Delivery Technology: Bringing Small Molecule Chemistry to Retinal Disease"
09/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO"
09/15/2021 8-K Quarterly results
09/08/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Overview Presentation dated September 2021",
"Company Overview Presentation dated September 2021"
08/11/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
07/20/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Approaches to Europe: Strategies for Development and Differentiation presentation",
"Approaches to Europe: Strategies for Development and Differentiation presentation"
06/21/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy